<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010439</url>
  </required_header>
  <id_info>
    <org_study_id>199/15705</org_study_id>
    <secondary_id>FD-R-001847-01</secondary_id>
    <nct_id>NCT00010439</nct_id>
  </id_info>
  <brief_title>Phase II Study of Alendronate Sodium in Children With High-Turnover Idiopathic Juvenile Osteoporosis</brief_title>
  <official_title>A Non-Randomized, Open-Label, Prospective, Non-Controlled, 12-Month Clinical Trial to Determine the Effects of Alendronate 35 or 70 mg/Week Depending Upon Body Weight, in Children and Adolescent With IJO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Determine the effects of alendronate sodium on skeletal remodeling and bone mineral
      density of the hip and spine in children with high-turnover idiopathic juvenile
      osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:

      Patients receive oral alendronate sodium weekly for 1 year. Treatment continues in the
      absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Participants With Increased Bone Mineral Density</measure>
    <time_frame>at 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with increase in bone mineral density at Lumbar Spine and/or Hip at 12 months as compared to the bone mineral density at Lumbar Spine and/or Hip obtained before therapy (baseline values)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants (1) With Fractures Before and After Therapy,(2)Analysed for Average Changes From High to Near Normal Mineral Apposition Rate (MAR) After Therapy,(3)Analysed for Average Insignificant Changes in Biochemical Markers After Therapy.</measure>
    <time_frame>Before and 12 months after treatment with alendronate</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Participants (pts) with fractures bef.and aft.therapy; pts analysed for average changes in mineral apposition rate (MAR) (high (1.9um/day) to near normal (1.2 um/day)as revealed in bone biopsies. MAR is the distance between the two tetracycline labels (um/day). The data represent the average of 10-17 measurements of the disltance obtained by reading 2-7 individual slides of bone biopsy and pts analysed for average insignificant biochemical markers (serum bone specific alkaline phosphatase for bone formation and urinary N-telopeptide for resorption)to determine the effect of therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1 Alendronate for 12 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.</description>
    <arm_group_label>1 Alendronate for 12 months</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:

          -  5-14 years of age

          -  Weight 20 kg or greater

          -  History of one or more atraumatic fracture

          -  Sexual development no greater than Tanner II

          -  Osteoporosis by DXA (Diagnosis of high-turnover osteoporosis with no underlying cause
             (e.g., malignancy, hyperthyroidism, hyperparathyroidism, or vitamin D intoxication)

        Inclusion Criteria:

          -  Male and female children with a history of one or more atraumatic fractures, or
             evidence of one or more compression fractures on radiographs of the spine (reduction
             of &gt;20%).

          -  Bone mineral density by DXA at 2 standard deviations (SD) below normal mean for age
             (Z-score at least 2 SD below normal mean at the lumbar spine or hip)

          -  Parental consent (and patient assent after age 12 years) to participate in the study.

          -  Sexual development at Tanner stage II or less (Prepubertal stage)

          -  Weight 20kg and more

        Exclusion Criteria:

          -  History of severe gastritis or reflux

          -  Marked kyphoscoliosis or inability to sit or stand for at least 30 minutes.

          -  Abnormalities of the esophagus that delay emptying (e.g., strictures or achalasia)

          -  Hypersensitivity to bisphosphonates

          -  Uncorrected hypocalcemia

          -  History of gastric or duodenal ulcers

          -  Renal dysfunction as indicated by serum Creatinine greater than 1.5 mg/dL

          -  Liver dysfunction as indicated by serum SGPT greater than 2 times upper limit of
             normal for age or serum total bilirubin greater than 2.0 mg/dL

          -  Diagnosis of osteogenesis imperfecta (including family history) or blue sclerae or
             deafness

          -  Diagnosis of active rickets, osteomalacia, or bone alkaline phosphatase &gt; 2 times
             normal for age

          -  Severe gastritis or reflux

          -  Pregnancy

          -  Anorexia Nervosa

               -  Prior/Concurrent Therapyâ€”

          -  Prior course of prednisone allowed

          -  No concurrent prednisone except inhaled steroids

          -  No concurrent high-dose glucocorticoids

          -  No concurrent salmon calcitonin

          -  No other concurrent bisphosphonates

          -  No concurrent long-term anti-seizure medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah A Bowlby, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>1. Key LL Jr., Ries w, Madyastha P, Reed F: Juvenile Osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab. 2003 May; 16 Suppl 3:683-6, PMID: 12795371 2. P Madyastha, W Ries, B Hollis, F Reed, L Key. Alendronate improved bone mineral density in patients with juvenile osteoporosis. JBMR 20:Suppl 1, page S400, 2005.</citation>
  </results_reference>
  <verification_date>October 2010</verification_date>
  <lastchanged_date>October 21, 2010</lastchanged_date>
  <firstreceived_date>February 2, 2001</firstreceived_date>
  <firstreceived_results_date>June 3, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Deborah A Bowlby, MD., Assistant Professor</name_title>
    <organization>Medical University of South Carolina</organization>
  </responsible_party>
  <keyword>arthritis &amp; connective tissue diseases</keyword>
  <keyword>idiopathic juvenile osteoporosis</keyword>
  <keyword>rare disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of the recruitment period: 5/3/2001 to 7/23/2002. Types of location: Out-patient clinic, Clinical and Translational Research Center (CTRC, formerly General Clinical Research Center), Medical University of South Carolina.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Alendronate</title>
          <description>Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alendronate</title>
          <description>Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>Pre-Treatment (Baseline)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9.4" spread="2.3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Post Treatment</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10.6" spread="2.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Increased Bone Mineral Density</title>
        <description>Number of participants with increase in bone mineral density at Lumbar Spine and/or Hip at 12 months as compared to the bone mineral density at Lumbar Spine and/or Hip obtained before therapy (baseline values)</description>
        <time_frame>at 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate</title>
            <description>Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Increased Bone Mineral Density</title>
            <description>Number of participants with increase in bone mineral density at Lumbar Spine and/or Hip at 12 months as compared to the bone mineral density at Lumbar Spine and/or Hip obtained before therapy (baseline values)</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10" spread="0.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants (1) With Fractures Before and After Therapy,(2)Analysed for Average Changes From High to Near Normal Mineral Apposition Rate (MAR) After Therapy,(3)Analysed for Average Insignificant Changes in Biochemical Markers After Therapy.</title>
        <description>Participants (pts) with fractures bef.and aft.therapy; pts analysed for average changes in mineral apposition rate (MAR) (high (1.9um/day) to near normal (1.2 um/day)as revealed in bone biopsies. MAR is the distance between the two tetracycline labels (um/day). The data represent the average of 10-17 measurements of the disltance obtained by reading 2-7 individual slides of bone biopsy and pts analysed for average insignificant biochemical markers (serum bone specific alkaline phosphatase for bone formation and urinary N-telopeptide for resorption)to determine the effect of therapy.</description>
        <time_frame>Before and 12 months after treatment with alendronate</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate</title>
            <description>Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participants (1) With Fractures Before and After Therapy,(2)Analysed for Average Changes From High to Near Normal Mineral Apposition Rate (MAR) After Therapy,(3)Analysed for Average Insignificant Changes in Biochemical Markers After Therapy.</title>
            <description>Participants (pts) with fractures bef.and aft.therapy; pts analysed for average changes in mineral apposition rate (MAR) (high (1.9um/day) to near normal (1.2 um/day)as revealed in bone biopsies. MAR is the distance between the two tetracycline labels (um/day). The data represent the average of 10-17 measurements of the disltance obtained by reading 2-7 individual slides of bone biopsy and pts analysed for average insignificant biochemical markers (serum bone specific alkaline phosphatase for bone formation and urinary N-telopeptide for resorption)to determine the effect of therapy.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Participants with fractures before therapy.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Participants with fractures after therapy.</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pts average MAR near normal after therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pts av biomarker change insignificant aft. therapy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Alendronate</title>
          <description>Ten children will take alendronate 35mg or 70mg weekly depending upon the body weight for 12 months. Patients will also take calcium supplement daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Agreement with Merck: to submit a copy of any proposed abstract, manuscript and/or press release to Merck for review and comment at least 30 days prior to submission for publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Deborah A Bowlby, M.D., Assistant Professor, Pediatric Endocrinology</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-6807</phone>
      <email>bowlbyd@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
